BeNeLuxBelgiumNetherlandsLuxembourg

Ablynx – highs and lows

16.12.2011

Ghent – Just days after US pharmaceuticals giant Pfizer pulled out of a rheumatoid arthritis pact with Ablynx NV, the Belgian biopharmaceutical company expanded its relationship with Merck Serono. Ablynx has now entered into a third agreement to discover and develop single-domain antibodies (‘Nanobodies’) together with the pharma giant against two targets in osteo­arthritis. Under the terms of the deal, Ablynx will receive an upfront payment of €20m.”Merck Serono is one of our most valued partners, and the innovative and creative deal structure that we have put in place represents a win-win situation for both parties,” said Ablynx CEO Edwin Moses. Merck is buying an all-inclusive package. Ablynx will be fully responsible for all activities and costs for each programme, excluding manufacturing, up to the delivery of the pre-clinical package that will form the basis of an Investigational New Drug filing or the equivalent. If Merck likes what it sees, Ablynx will receive a further €15m for each programme.

BeNeLuxBelgiumNetherlandsLuxembourg

05.10.2011

Luxembourg - For its tiny size, Luxembourg attracts a disproportionally huge amount of venture capital. Creabilis SA has raised €15m in a Series B funding round led by Abbott Biotech Ventures. "In Abbott, we have added another...

BeNeLuxBelgiumNetherlandsLuxembourg

01.10.2011

Munich/Amsterdam – Researchers from the LMU Munich and the Aca­demic Medical Center Amsterdam have found a way to predict disease outcome in patients with life-threatening bacterial meningitis. In a nation­wide genetic...

BeNeLuxBelgiumNetherlandsLuxembourg

01.10.2011

Utrecht – Consuming fish or fish oil capsules may be a bad idea for cancer patients, according to Dutch researchers. In mid-September, a team headed by Emile Voest from the University Medical Centre Utrecht reported such products...

BeNeLuxBelgiumNetherlandsLuxembourg

01.10.2011

Rotterdam – Finnish oil refining company Neste Oil corporation has kick-started production in Europe’s largest renewable diesel refinery in Rotterdam. The plant has a capacity of 800,000 tonnes a year, and this will be ramped up...

BeNeLuxBelgiumNetherlandsLuxembourg

01.10.2011

Brussels – A European gateway to life science capacities has been launched (www.toolsofscience.eu) that is aimed at providing a novel resource for identifying the best facilities and service companies from among 13 bioregions...

BeNeLuxBelgiumNetherlandsLuxembourg

01.10.2011

Stockholm/Leiden/Barcelona – A complicated ménage a trois has come to an end: Swedish Orphan Biovitrum AB, Pharming Group N.V. and Esteve S.A. announced at the beginning of September that they were terminating a 2004 deal...

BeNeLuxBelgiumNetherlandsLuxembourg

14.09.2011

Bunnik – AM-Pharma B.V. has raised €29.2m. The Dutch company plans to spend the money on delivering a human recombinant form of Alkaline Phosphatase (AP) as a treatment for Acute Kidney Injury (AKI) from preclinical stages to the...

BeNeLuxBelgiumNetherlandsLuxembourg

13.09.2011

Utrecht – Researchers at University Medical Center Utrecht have dealt a blow to the advocates of allegedly healthy fish oil. The substance which is again and again named as a helpful substance for cancer patients, seems instead...

BeNeLuxBelgiumNetherlandsLuxembourg

07.09.2011

Diepenbeek - Amakem has received €18m to take a glaucoma drug candidate through Phase II trials. The Belgium-based developer lead candidate will use the money to advance its lead candidate AMA0076 to the clinical proof of...

Displaying results 21 to 30 out of 304

< Previous 21-30 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-benelux/browse/2/article/ablynx-highs-and-lows.html

Events

All Events

Stock list

All quotes

TOP

  • CO.DON3.13 EUR5.03%
  • 4SC1.06 EUR3.92%
  • SANTHERA88.65 CHF2.78%

FLOP

  • CYTOS0.19 CHF-9.52%
  • WILEX2.13 EUR-6.99%
  • FORMYCON8.03 EUR-5.42%

TOP

  • PAION3.18 EUR33.6%
  • CO.DON3.13 EUR27.8%
  • FORMYCON8.03 EUR14.2%

FLOP

  • CYTOS0.19 CHF-26.9%
  • ADDEX3.13 CHF-18.1%
  • EVOTEC3.06 EUR-16.8%

TOP

  • SANTHERA88.65 CHF2155.7%
  • PAION3.18 EUR224.5%
  • CO.DON3.13 EUR222.7%

FLOP

  • CYTOS0.19 CHF-95.2%
  • 4SC1.06 EUR-43.9%
  • THERAMETRICS0.08 CHF-42.9%

No liability assumed, Date: 30.09.2014


Current issue

All issues

Product of the week

Products